InvestorWire NewsRoom

Article

RYAH Group Inc. (CSE: RYAH) to Deliver Solutions for Clinicians Examining Cannabis Efficacy in Cancer Treatment
December 7, 2021

RYAH Group Inc. (CSE: RYAH) to Deliver Solutions for Clinicians Examining Cannabis Efficacy in Cancer Treatment

  • Multiple ongoing studies are researching the relationship between medical cannabis and cancer treatment
  • The viability of clinical studies within the sector is hampered by lack of exact measurement of a patient’s intake
  • RYAH Group intends to resolve this issue with the launch of it’s proprietary RYAH Smart Dry Herb Inhaler
  • The company successfully delivered on its first Inhaler order in May 2021, and announced that they had received a follow-on order in November 2021

In 1980, The United States National Cancer Institute (“NCI”) began experimental distribution of a novel drug called Marinol, an oral form of THC (the primary active ingredient in cannabis), to cancer patients in San Francisco (https://ibn.fm/HE5vn). Just over a decade later, the city of San Francisco celebrated the passing of Proposition P in 1991, a revolutionary bill that legalized the use of medical cannabis within the city limits. There’s an abundance of evidence supporting the use of medical cannabis to treat cancer symptoms. Now, rather than just treating symptoms, science has begun to ask, “could cannabis be used to treat cancer itself”? 

A recognized leader in volume management technology for plant-based medicine, RYAH Group (CSE: RYAH) is in the middle of the action. RYAH develops innovative IoT products that capture powerful data insights and is on a mission to to transform patient care using big data and AI to reshape understanding and uses of plant-based medicines. The company’s robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which then helps doctors and patients personalize plant-based treatments to better predict treatment outcomes. Little wonder that RYAH devices and data are being used by a rapidly growing number of participants in plant-based clinical trials around the world.

While clinical research into the relationship between medical cannabis consumption and cancer treatment is in the very early stages, initial studies have shown that THC and other cannabinoids bind to the endocannabinoid receptors on cancer cells, thereby interrupting the cell’s ability to signal. With limited intracellular signals, the studies have witnessed increased cancer cell apoptosis, reduced proliferation, migration, and metastasis (https://ibn.fm/rSirx).

Two key constraints that have limited the viability of cannabis studies within an oncological setting are the highly variable nature of the cannabis plant and traditional methods of cannabis consumption that make patient intake challenging to measure. 

The RYAH Group intends to resolve this issue with the launch of their proprietary RYAH Smart Dry Herb Inhaler. The product is the first dry-herb inhaler that tracks and controls how much is inhaled, providing consistent and predictable results. The inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and measurements, all of which can be customized to individual needs and doctor recommendations. Moreover, the device also permits a post-session review mechanism that collects session data, an essential requirement for any clinical study.

In June 2021, the RYAH Group announced that it had completed its first shipment of RYAH Smart Dry Herb Inhalers, which included delivery of approximately 10,000 RYAH Cartridges and QR codes, to an international clinic undertaking one of the world’s largest and most comprehensive clinical trials in plant-based medicine (https://ibn.fm/XkFrG). In early November, the company announced that it had received a separate, follow-on order for its proprietary Inhaler product from the same company (https://ibn.fm/gALMy).

While it is far too early for patients to forego traditional oncological treatments in favor of standalone medical cannabis therapy, clinical trials worldwide seek to discern the relationship between medical cannabis consumption and cancer treatment. 

While the trials currently lie at a relatively nascent stage, RYAH Group and its diverse and proprietary volume control and management device portfolio are playing their part in what may, one day, turn out to be a genuinely revolutionary medical breakthrough.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).